Dr. Reddy’s Laboratories Ltd $RDY Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 19.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 351,469 shares of the company’s stock after acquiring an additional 56,760 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $4,914,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Westside Investment Management Inc. acquired a new position in shares of Dr. Reddy’s Laboratories during the second quarter valued at approximately $35,000. EverSource Wealth Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 71.7% during the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after purchasing an additional 1,294 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Dr. Reddy’s Laboratories by 217.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock valued at $50,000 after purchasing an additional 2,444 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Dr. Reddy’s Laboratories in the 2nd quarter valued at $67,000. Finally, Allworth Financial LP boosted its stake in Dr. Reddy’s Laboratories by 37.8% during the 2nd quarter. Allworth Financial LP now owns 4,827 shares of the company’s stock worth $73,000 after purchasing an additional 1,323 shares during the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Dr. Reddy’s Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Trading Down 2.5%

RDY stock traded down $0.35 during trading on Wednesday, reaching $13.37. 74,479 shares of the stock were exchanged, compared to its average volume of 1,622,922. The company has a current ratio of 1.88, a quick ratio of 1.38 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $11.16 billion, a price-to-earnings ratio of 17.34, a P/E/G ratio of 12.18 and a beta of 0.37. The business has a 50 day moving average price of $13.82 and a 200-day moving average price of $14.07. Dr. Reddy’s Laboratories Ltd has a 1 year low of $12.26 and a 1 year high of $16.17.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $969.81 million for the quarter, compared to analyst estimates of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%. On average, research analysts predict that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India?based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost?effective generic treatments for branded drugs that have lost patent protection, along with in?house research into innovative molecule development.